Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of patients and offering new hope for those with the life-threatening condition.

Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Results from the ESSENCE phase 3 clinical trial published today in the New England Journal of ...

Fat cells are also metabolically active and can cause a chronic state of inflammation in the part of the body where they ...

A new American Diabetes Association consensus statement provides guidance on screening, diagnosing, and managing metabolic ...

Metabolic dysfunction–associated steatohepatitis (MASH) is a form of liver disease that can progress ... to evaluate the GLP-1 receptor agonist semaglutide in patients with MASH and stage ...

The ability to not just halt but potentially reverse this scarring process could transform how we approach advanced liver disease treatment. Participants receiving semaglutide experienced an ...

Semaglutide Treats Liver Disease in Two Thirds of Patients Apr. 30, 2025 — Semaglutide effectively treats liver disease in two thirds of patients, new research has ... Apr. 15, 2025 ...

Discover a recent study where the authors propose a strategic push to double the diagnostic rate of at-risk MASH by 2030.

Individuals with diabetes and hypertension are especially at risk and should undergo screening for NAFLD (Non-Alcoholic Fatty ...

Improves fibrosis and steatohepatitis Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a broad ...

Results from the ESSENCE Phase III clinical trial published in the New England Journal of Medicine show treating patients with semaglutide can halt and even reverse liver disease. The placebo ...